“…These markers include differences in mtDNA sequences identified in the cytochrome oxidase I (COI), and NADH dehydrogenase genes (Pashley, 1989;Lu & Adang, 1996;Levy et al, 2002;Nagoshi et al, 2006a), as well as nuclear DNA differences, including restriction length fragment polymorphisms (RFLPs) (Lu et al, 1992), amplified fragment length polymorphisms (AFLPs) (McMichael & Prowell, 1999;Busato et al, 2004;Clark et al, 2007;Martinelli et al, 2007;Belay et al, 2012), polymorphisms in tandem-repeat sequences (FRs) (Lu et al, 1994;Nagoshi & Meagher, 2003a,b), and 10 polymorphisms in the sex-linked triose phosphate isomerase gene (Tpi) (Nagoshi, 2010). These markers include differences in mtDNA sequences identified in the cytochrome oxidase I (COI), and NADH dehydrogenase genes (Pashley, 1989;Lu & Adang, 1996;Levy et al, 2002;Nagoshi et al, 2006a), as well as nuclear DNA differences, including restriction length fragment polymorphisms (RFLPs) (Lu et al, 1992), amplified fragment length polymorphisms (AFLPs) (McMichael & Prowell, 1999;Busato et al, 2004;Clark et al, 2007;Martinelli et al, 2007;Belay et al, 2012), polymorphisms in tandem-repeat sequences (FRs) (Lu et al, 1994;Nagoshi & Meagher, 2003a,b), and 10 polymorphisms in the sex-linked triose phosphate isomerase gene (Tpi) (Nagoshi, 2010).…”